Acer Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acer Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q3 2023.
  • Acer Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $233K, a 49.5% decline year-over-year.
  • Acer Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $1.22M, a 36.5% decline year-over-year.
  • Acer Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.84M, a 19.5% decline from 2021.
  • Acer Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $2.29M, a 2.83% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $1.22M $233K -$228K -49.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-20
Q2 2023 $1.45M $260K -$201K -43.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $1.65M $286K -$189K -39.8% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $1.84M $446K -$87.4K -16.4% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-27
Q3 2022 $1.93M $460K -$140K -23.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-20
Q2 2022 $2.07M $461K -$134K -22.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $2.2M $474K -$85.3K -15.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $2.29M $533K +$67.1K +14.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 $2.22M $600K +$113K +23.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $2.11M $595K -$8.91K -1.48% Apr 1, 2021 Jun 30, 2021 10-Q/A 2022-11-14
Q1 2021 $2.12M $559K -$108K -16.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $2.22M $466K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 $487K -$76.6K -13.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-19
Q2 2020 $604K -$112K -15.6% Apr 1, 2020 Jun 30, 2020 10-Q/A 2021-11-19
Q1 2020 $667K -$4.59K -0.68% Jan 1, 2020 Mar 31, 2020 10-Q/A 2021-11-19
Q3 2019 $564K +$211K +59.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $715K +$389K +119% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $672K +$420K +166% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 $353K +$247K +233% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $326K +$312K +2114% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $252K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 $106K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $14.7K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2016 $154K -$113K -42.4% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-12
Q1 2015 $267K -$64.1K -19.4% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
Q1 2014 $331K Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.